Emerging tyrosine kinase inhibitors for esophageal cancer

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004;31:450-64
   PubMed Web of Science ®Google Scholar
• Devesa SS, Fraumeni JF Jr. The rising incidence of gastric cardia cancer. J Natl Cancer Inst 1999;91:747-9
   PubMed Web of Science ®Google Scholar
• Kattan MW, Karpeh MS, Mazumdar M, et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003;21:3647-50
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999;230:392-400; discussion 400-3
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
   PubMed Web of Science ®Google Scholar
• Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-92
   PubMed Web of Science ®Google Scholar
• Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52
   PubMed Web of Science ®Google Scholar
• Ezdinli EZ, Gelber R, Desai DV, et al. Chemotherapy of advanced esophageal carcinoma: eastern Cooperative Oncology Group experience. Cancer 1980;46:2149-53
   PubMed Web of Science ®Google Scholar
• Lokich JJ, Shea M, Chaffey J. Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction. Cancer 60:275-9.1987
   PubMed Web of Science ®Google Scholar
• Davis S, Shanmugathasa M, Kessler W. cis-Dichlorodiammineplatinum(II) in the treatment of esophageal carcinoma. Cancer Treat Rep 1980;64:709-11
   PubMedGoogle Scholar
• Murthy SK, Prabhakaran PS, Chandrashekar M, et al. Neoadjuvant Cis-DDP in esophageal cancers: an experience at a regional cancer centre, India. J Surg Oncol 1990;45:173-6
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ajani JA, Karlin DA. Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology 1985;42:69-71
   PubMed Web of Science ®Google Scholar
• Desai PB, Borges EJ, Vohra VG, et al. Carcinoma of the esophagus in India. Cancer 1969;23:979-89
   PubMed Web of Science ®Google Scholar
• Engstrom PF, Lavin PT, Klaassen DJ. Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat Rep 1983;67:713-15
   PubMedGoogle Scholar
• Whittington RM, Close HP. Clinical experience with mitomycin C (NSC-26980). Cancer Chemother Rep 1970;54:195-8
   PubMedGoogle Scholar
• Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004;15:1344-7
   PubMed Web of Science ®Google Scholar
• Koizumi W, Saigenji K, Ujiie S, et al. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003;64:232-6
   PubMed Web of Science ®Google Scholar
• Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-9
   PubMed Web of Science ®Google Scholar
• Chollet P, Schoffski P, Weigang-Kohler K, et al. Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 2003;39:1264-70
   PubMed Web of Science ®Google Scholar
• Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20
   PubMed Web of Science ®Google Scholar
• Ilson D, Wadleigh R, Leichman L, et al. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007;18:898-902
   PubMed Web of Science ®Google Scholar
• Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-91
   PubMed Web of Science ®Google Scholar
• Anderson SE, O'Reilly EM, Kelsen DP, et al. Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest 2003;21:512-16
   PubMed Web of Science ®Google Scholar
• Einzig AI, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996;13:87-93
   PubMed Web of Science ®Google Scholar
• Heath EI, Urba S, Marshall J, et al. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs 2002;20:95-9
   PubMed Web of Science ®Google Scholar
• Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15:955-9
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005;50:2218-23
   PubMed Web of Science ®Google Scholar
• Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010(3):CD004064
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
   PubMed Web of Science ®Google Scholar
• Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007;298:70-82
   PubMed Web of Science ®Google Scholar
• Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988;57:443-78
   PubMed Web of Science ®Google Scholar
• Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74:795-804
   PubMed Web of Science ®Google Scholar
• Kitagawa Y, Ueda M, Ando N, et al. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996;2:909-14
   PubMed Web of Science ®Google Scholar
• Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005;93:107-15
   PubMed Web of Science ®Google Scholar
• Wilkinson NW, Black JD, Roukhadze E, et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 2004;8:448-53
   PubMed Web of Science ®Google Scholar
• Waddell T, Chau I, Barbachano Y, et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3) [abstract]. J Clin Oncol 2012;30:LBA4000
   Google Scholar
• Lordick F, Bodoky G, Chung H, et al. Cetuximab in combination with capecitabine and cisplatin as first-line treatment in advanced gastric cancer: randomized controlled phase III EXPAND study [abstract]. Ann Oncol 2012;23:LBA3
   Google Scholar
• Crosby T, Hurt C, Falk S, et al. SCOPE 1: a phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab [abstract]. J Clin Oncol 2013;30:LBA3
   Google Scholar
• Herbst RS, Fukuoka M, Baselga J. Gefitinib–a novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956-65
   PubMed Web of Science ®Google Scholar
• Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010;5:229-35
   PubMed Web of Science ®Google Scholar
• Javle M, Pande A, Iyer R, et al. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol 2008;31:329-34
   PubMed Web of Science ®Google Scholar
• Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007;13:5869-75
   PubMed Web of Science ®Google Scholar
• Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24:1612-19
   PubMed Web of Science ®Google Scholar
• Ferry D, Dutton S, Mansoor W, et al. Phase III multi-centre, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib) [abstract]. Ann Oncol 2012;23(suppl 9):LBA20
   Google Scholar
• Ilson DH, Kelsen D, Shah M, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 2011;117:1409-14
   PubMed Web of Science ®Google Scholar
• Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-7
   PubMed Web of Science ®Google Scholar
• Casalini P, Iorio MV, Galmozzi E, et al. Role of HER receptors family in development and differentiation. J Cell Physiol 2004;200:343-50
   PubMed Web of Science ®Google Scholar
• al-Kasspooles M, Moore JH, Orringer MB, et al. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993;54:213-19
   PubMed Web of Science ®Google Scholar
• Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68
   PubMed Web of Science ®Google Scholar
• Chan DS, Twine CP, Lewis WG. Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. J Gastrointest Surg 2012;16:1821-9
   PubMed Web of Science ®Google Scholar
• Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012;18:546-54
   PubMed Web of Science ®Google Scholar
• Brien TP, Odze RD, Sheehan CE, et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000;31:35-9
   PubMed Web of Science ®Google Scholar
• Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes–a systematic review. Int J Cancer 2012;130:2845-56
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012;23:2656-62
   PubMed Web of Science ®Google Scholar
• Okines AF, Thompson LC, Cunningham D, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol 2013;24:1253-61
   PubMed Web of Science ®Google Scholar
• Terashima M, Kitada K, Ochiai A, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012;18:5992-6000
   PubMed Web of Science ®Google Scholar
• Iqbal S, Goldman B, Fenoglio-Preiser CM, et al. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011;22:2610-15
   PubMed Web of Science ®Google Scholar
• Hecht J, Urba S, Koehler M, et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase II efficacy and biomarker analyses [abstract]. Proc GI ASCO 2008;43
   Google Scholar
• Galsky MD, Von Hoff DD, Neubauer M, et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 2012;30:695-701
   PubMed Web of Science ®Google Scholar
• Bang Y. A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: tytan study [abstract]. J Clin Oncol 2013;30:11
   Google Scholar
• Oh D, Lee K, Cho J, et al. A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen [abstract]. J Clin Oncol 2012;30:54
   Google Scholar
• Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1-8
   PubMedGoogle Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25
   PubMed Web of Science ®Google Scholar
• Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127-39
   PubMed Web of Science ®Google Scholar
• Inoue K, Ozeki Y, Suganuma T, et al. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997;79:206-13
   PubMed Web of Science ®Google Scholar
• Kitadai Y, Haruma K, Tokutomi T, et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998;4:2195-200
   PubMed Web of Science ®Google Scholar
• Kleespies A, Guba M, Jauch KW, et al. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004;87:95-104
   PubMed Web of Science ®Google Scholar
• Shih CH, Ozawa S, Ando N, et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000;6:1161-8
   PubMed Web of Science ®Google Scholar
• Imdahl A, Bognar G, Schulte-Monting J, et al. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002;21:657-63
   PubMed Web of Science ®Google Scholar
• Shimada H, Hoshino T, Okazumi S, et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002;86:552-7
   PubMed Web of Science ®Google Scholar
• Mobius C, Stein HJ, Becker I, et al. The 'angiogenic switch' in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 2003;29:890-4
   PubMed Web of Science ®Google Scholar
• Vallbohmer D, Peters JH, Kuramochi H, et al. Molecular determinants in targeted therapy for esophageal adenocarcinoma. Arch Surg 2006;141:476-81; discussion 481-2
   PubMed Web of Science ®Google Scholar
• Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-63
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Tsuburaya A, Kobayashi O, et al. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000;153:7-12
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-76
   PubMed Web of Science ®Google Scholar
• Shah M, Van Cutsem E, Kang Y, et al. Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer [abstract]. J Clin Oncol 2012;30:5
   Web of Science ®Google Scholar
• Fuchs C, Tomasek J, Cho J, et al. REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy [abstract]. J Clin Oncol 2013;30:LBA5
   Google Scholar
• Moehler M, Mueller A, Hartmann JT, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011;47:1511-20
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011;29:1449-58
   PubMed Web of Science ®Google Scholar
• Yi JH, Lee J, Lee J, et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012;106:1469-74
   PubMed Web of Science ®Google Scholar
• Schmitt JM, Sommers SR, Fisher W, et al. Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol 2012;7:760-3
   PubMed Web of Science ®Google Scholar
• Knox J, Wong R, Darling G, et al. Adjuvant sunitinib (Su) for locally advanced esophageal cancer (LAEC): results of a phase II trial [abstract]. J Clin Oncol 2011;29:4091
   Google Scholar
• Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28:2947-51
   PubMed Web of Science ®Google Scholar
• Kim C, Lee JL, Choi YH, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs 2012;30:306-15
   PubMed Web of Science ®Google Scholar
• Grothey A, Cutsem EV, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;383:303-12
   Google Scholar
• Li J, Qin S, Xu J, et al. A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma [abstract]. J Clin Oncol 2011;29:4019
   Google Scholar
• Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009;59:111-37
   PubMed Web of Science ®Google Scholar
• Yu G, Wang J, Chen Y, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 2009;15:1821-9
   PubMed Web of Science ®Google Scholar
• Yu HG, Ai YW, Yu LL, et al. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 2008;122:433-43
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Yeh K, Bang Y, et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1 [abstract]. J Clin Oncol 2012;30:LBA3
   Google Scholar
• Jhawer M, Kindler H, Wainberg Z, et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): interim results of a multicenter phase II study [abstract]. J Clin Oncol 2009;27:4502
   Google Scholar
• Bachleitner-Hofmann T, Sun MY, Chen CT, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 2008;7:3499-508
   PubMed Web of Science ®Google Scholar
• Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-902
   PubMed Web of Science ®Google Scholar
• Tuynman JB, Lagarde SM, Ten Kate FJ, et al. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 2008;98:1102-8
   PubMed Web of Science ®Google Scholar
• Oliner K, Tang R, Anderson A, et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer [abstract]. J Clin Oncol 2012;30:4005
   Google Scholar
• Muro K, Ryu M, Yasui H, et al. A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer[abstract]. J Clin Oncol 2012;30:4082
   Google Scholar
• Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008;135:255-60; discussion 260
   PubMed Web of Science ®Google Scholar
• Kwong KF. Molecular biology of esophageal cancer in the genomics era. Surg Clin North Am 2005;85:539-53
   PubMed Web of Science ®Google Scholar
• Lin J, Beerm DG. Molecular biology of upper gastrointestinal malignancies. Semin Oncol 2004;31:476-86
   PubMed Web of Science ®Google Scholar
• Cervantes A, Rodriguez Braun E, Perez Fidalgo A, et al. Molecular biology of gastric cancer. Clin Transl Oncol 2007;9:208-15
   PubMed Web of Science ®Google Scholar
• Ooi CH, Ivanova T, Wu J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet 2009;5:e1000676
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68:3077-80; discussion 3080
   PubMed Web of Science ®Google Scholar